Survival analysis by online tool Kaplan Meier-plotter showed elevated ECT2 mRNA level indicated poor prognosis of breast cancer patients (PFS: HR = 1.69, log-rank P < 0.0001; OS: HR = 1.44, log-rank P = 0.001; Distant metastasis-free survival: HR = 1.47, log-rank P = 0.00016; Post progression survival: HR = 1.52, log-rank P = 0.00091) (Fig. 7C–F). Here, ECT2 is linked to breast carcinoma.